Work

First-line lorlatinib achieves durable systemic and intracranial response in EML4-ALK positive large-cell neuroendocrine carcinoma: a case report with DNA/RNA fusion discordance

Year: 2026
Type: article
Study design: Case Report
Abstract: Background Lorlatinib, a third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI), is the current first-line standard of care for advanced non-small cell lung cancer (NSCLC) harboring EML4-ALK rearrangement. However, ALK rearrangements are rarely identified in pulmonary large-cell neuroendocrine carcinoma (LCNEC), and clinical evidence supporting ALK TKI directed therapy in this population remains limited. Case presentation We report a 35-year-old man diagnosed with advanced large-cell neuroendocrine carcinoma (LCNEC) carrying an EML4-ALK rearrangement. First-line lorlatinib resulted in rapid systemic tumor regression and complete intracranial response. At the data cutoff, the patient's progression-free survival had not been reached at 13.47 months with good tolerability. DNA-based next-generation sequencing identified two ALK rearrangements, whereas RNA-based sequencing detected only the canonical EML4-ALK rearrangement transcript. Testicular pain occurred during treatment and improved after dose modification; however, a definitive causal relationship could not be established. Conclusion This case report demonstrates the efficacy of lorlatinib as first-line therapy for large-cell neuroendocrine carcinoma with ALK rearrangement. The observed DNA/RNA fusion discordance also illustrates the complementary roles of DNA- and RNA-based testing in interpreting complex genomic rearrangements.
Language: English
Field: Medicine
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W7236083748
FWCI:
Cites: 27
Cited by:
Related to: 10